Robbins LLP Reminds REGN Shareholders to Seek Counsel for the Regeneron Pharmaceuticals, Inc. Class Action

Group 1 - A class action has been filed against Regeneron Pharmaceuticals, Inc. for allegedly misleading investors regarding its business prospects during the period from November 2, 2023, to October 30, 2024 [1][2] - The allegations include undisclosed payments made by Regeneron to distributors to subsidize credit card fees, which resulted in misleadingly reported sales figures for Eylea, a key product [2] - The complaint claims that Regeneron's failure to report these payments as price concessions led to an overstatement of the Average Selling Price (ASP) reported to federal agencies, violating the False Claims Act [2] Group 2 - Shareholders interested in participating as lead plaintiffs in the class action must submit their applications by March 4, 2025 [3] - The representation in the class action is on a contingency fee basis, meaning shareholders will not incur any fees or expenses [4] - Robbins LLP, the firm leading the class action, has a history of advocating for shareholder rights and holding company executives accountable since 2002 [4]